**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
Giorgia Canali, Pfizer, Paris, France  
Giorgia.canali@pfizer.com

**Main Body of the Abstract**
Background: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a rare, progressively debilitating, fatal disease. With no specific treatment available before 2018, ATTR-CM is still often under-diagnosed and reliable epidemiological data are still needed on this disease.
Objective: To estimate the annual incidence of ATTR-CM in France between 2011 and 2021 and describe characteristics of incident patients.
Material & Methods: We used the French nationwide claims database. As there is no specific ICD-10 marker code for ATTR-CM, diagnosis required both amyloidosis (identified by E85 code or tafamidis delivery) and cardiovascular condition (identified by ICD-10 codes of heart failure, arrhythmias, conduction disorders or cardiomyopathies), not necessarily reported at the same visit. Patients with probable AL-form or AA-form of amyloidosis were excluded.
Results: Between 2011 and 2021, 15,269 patients with incident ATTR-CM were identified. For 13,737 of them, the cardiovascular condition was coded first, and amyloidosis in second. Incidence rates increased from 0.6/100,000 person-years in 2011 to 5.1/100,000 person-years in 2021 (p<0.001), reaching 3,443 new cases in 2021. Crude incidence varied according to the Department of residence. Sex ratio (M/F) increased from 1.56 in 2011 to 2.14 in 2021. Median age at diagnosis was 83.0 years (85.0 for women and 83.0 for men), and increased over the period (81 years between 2011 and 2017, to reach 85 years in 2021)
Summary & Conclusion: We observed an increase in ATTR-CM incidence over the study period, consistent with an improvement in ATTR-CM diagnosis in recent years.
Support & Funding: This study was sponsored by Pfizer.



**Author Listing - Lead/ Submitting Author (we will be communicating with this individual): Name, Institution, City and State where the work was done. Co-authors will be added in a separate section.**
**Giorgia Canali, Pfizer,** Paris, France  
[Giorgia.canali@pfizer.com](mailto:Giorgia.canali@pfizer.com)

**Main Body of the Abstract**
**Background:** Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a rare, progressively debilitating, fatal disease. With no specific treatment available before 2018, ATTR-CM is still often under-diagnosed and reliable epidemiological data are still needed on this disease.
**Objective:** To estimate the annual incidence of ATTR-CM in France between 2011 and 2021 and describe characteristics of incident patients.
**Material & Methods:** We used the French nationwide claims database. As there is no specific ICD-10 marker code for ATTR-CM, diagnosis required both amyloidosis (identified by E85 code or tafamidis delivery) and cardiovascular condition (identified by ICD-10 codes of heart failure, arrhythmias, conduction disorders or cardiomyopathies), not necessarily reported at the same visit. Patients with probable AL-form or AA-form of amyloidosis were excluded.
**Results:** Between 2011 and 2021, 15,269 patients with incident ATTR-CM were identified. For 13,737 of them, the cardiovascular condition was coded first, and amyloidosis in second. Incidence rates increased from 0.6/100,000 person-years in 2011 to 5.1/100,000 person-years in 2021 (p<0.001), reaching 3,443 new cases in 2021. Crude incidence varied according to the Department of residence. Sex ratio (M/F) increased from 1.56 in 2011 to 2.14 in 2021. Median age at diagnosis was 83.0 years (85.0 for women and 83.0 for men), and increased over the period (81 years between 2011 and 2017, to reach 85 years in 2021)
**Summary & Conclusion:** We observed an increase in ATTR-CM incidence over the study period, consistent with an improvement in ATTR-CM diagnosis in recent years.
**Support & Funding:** This study was sponsored by Pfizer.



Incidence of transthyretin amyloid cardiomyopathy from a French nationwide study of in- and out-patient databases PA26 (#117)

We invite you to attend the XIX International Symposium on Amyloidosis to be held in Rochester, MN.

This symposium is organized as a hybrid meeting (with the focus on in-person) held from Sunday, May 26 through Thursday, May 30, 2024.

Together with the ISA Board and members of Mayo Clinic, a very attractive scientific hybrid program is being planned. The program will cover a variety of types of systemic amyloidosis: ATTR (hereditary and wild-type), AL (light-chain), AA and less frequent forms. There will be key lectures, specific symposia including those company sponsored, oral presentations and poster sessions of accepted abstracts.

COURSE DESCRIPTION
This program will provide a comprehensive review of state-of-the-art education in systemic amyloidosis: basic science, pathophysiology, diagnosis, current and emerging treatments. Scientific presentations will include competitive oral and poster abstracts. The rapid evolution of scientific discovery and expanding treatment options has created tremendous interest in the field and this meeting will fill and important gap in educating scientists and clinicians.